Sam England

Sam England of Berenberg asked about the potential market share gains from the CatellaStem hip system, particularly in the ASC channel, and questioned the demand drivers for the CORI robotics system between hospital and ASC settings.

Answer

CEO Deepak Nath expressed satisfaction with the uptake of CatellaStem and its strong surgeon feedback across all settings. For the CORI robotics system, he highlighted that the focus is on both placements and utilization, with encouraging progress in ASCs and teaching institutions. CFO John Rogers added that CORI placements over-indexed in ASCs during Q2, reinforcing its strong fit for that channel due to its smaller footprint and lower capital cost.

Sam England of Berenberg asked about the potential market share gains from the CatellaStem hip system, particularly in the ASC channel, and inquired about the demand drivers for the CORI robotic system, specifically the split between hospital and ASC placements.

Answer

CEO Deepak Nath expressed satisfaction with the uptake of CatellaStem, noting strong surgeon feedback in the growing direct anterior approach segment. On robotics, he emphasized the focus is on both placements and utilization, with encouraging progress in ASCs. CFO John Rogers added that in Q2, CORI placements 'over-indexed' in ASCs, where its smaller footprint and lower capital cost are significant advantages.

Asked for clarification on whether positive pricing was across all segments, the drivers for growth in Wound Devices, and the specific 12-Point Plan initiatives impacting that growth.

Answer

Positive pricing was achieved across all three business units and across geographies, not just in aggregate. The growth in negative pressure wound therapy is primarily driven by the new product launch of RENASYS EDGE, which is in its early stages and is expected to be a multiyear growth platform.